{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:57:04Z","timestamp":1790629024050,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.lfs.2022.120731","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T23:34:14Z","timestamp":1656027254000},"page":"120731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity"],"prefix":"10.1016","volume":"305","author":[{"given":"Mohamed Fawzi","family":"Kabil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Y.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa F.","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Zaafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim M.","family":"El-Sherbiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2022.120731_bb0010","series-title":"Breast Cancer","first-page":"199","article-title":"Approaching neoadjuvant therapy in the management of early-stage breast cancer","volume":"13","author":"Hyder","year":"2021"},{"issue":"7","key":"10.1016\/j.lfs.2022.120731_bb0015","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s43018-021-00229-1","article-title":"Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment","volume":"2","author":"Pasha","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.lfs.2022.120731_bb0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.addr.2017.04.003","article-title":"Nanoformulation-based sequential combination cancer therapy","volume":"115","author":"Shim","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2022.120731_bb0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2022.120731_bb0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.semcancer.2019.09.012","article-title":"Drug repurposing for breast cancer therapy: old weapon for new battle","volume":"68","author":"Aggarwal","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.lfs.2022.120731_bb0035","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.lfs.2022.120731_bb0045","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-017-4372-6","article-title":"Repurposing metformin for the prevention of cancer and cancer recurrence","volume":"60","author":"Heckman-Stoddard","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2022.120731_bb0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.biopha.2018.09.013","article-title":"Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; effects independent of substance P","volume":"108","author":"Nizam","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.lfs.2022.120731_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12092682","article-title":"The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer?","volume":"12","author":"Mu\u00f1oz","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.lfs.2022.120731_bb0060","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2174\/1389557519666191112152642","article-title":"Triple negative breast cancer: how neurokinin-1 receptor antagonists could be used as a new therapeutic approach","volume":"20","author":"Mu\u00f1oz","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"issue":"16","key":"10.1016\/j.lfs.2022.120731_bb0065","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s40265-015-0485-8","article-title":"Rolapitant: first global approval","volume":"75","author":"Syed","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2022.120731_bb0070","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.2147\/DDDT.S133943","article-title":"Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations","volume":"11","author":"Rapoport","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"issue":"22","key":"10.1016\/j.lfs.2022.120731_bb0075","doi-asserted-by":"crossref","first-page":"18748","DOI":"10.18632\/oncotarget.4349","article-title":"Targeting cancer by binding iron: dissecting cellular signaling pathways","volume":"6","author":"Lui","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.lfs.2022.120731_bb0080","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3495","article-title":"Iron and cancer: more ore to be mined","volume":"13","author":"Torti","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2022.120731_bb0085","doi-asserted-by":"crossref","unstructured":"E. Gumienna-Kontecka, M. Pyrkosz-Bulska, A. Szebesczyk, and M. Ostrowska, \u201cIron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer,\u201d Current Medicinal Chemistry, vol. 21, no. 33. pp. 3741\u20133767, [Online]. Available: https:\/\/www.ingentaconnect.com\/content\/ben\/cmc\/2014\/00000021\/00000033\/art00003.","DOI":"10.2174\/0929867321666140706143402"},{"issue":"2","key":"10.1016\/j.lfs.2022.120731_bb0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bmcl.2015.11.094","article-title":"Recent advances in cancer treatment by iron chelators","volume":"26","author":"Corc\u00e9","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.lfs.2022.120731_bb0095","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1023\/B:NEON.0000024238.21349.37","article-title":"Desferoxamine (DFO) \u2013 mediated iron chelation: rationale for a novel approach to therapy for brain cancer","volume":"67","author":"Dayani","year":"2004","journal-title":"J. Neuro-Oncol."},{"issue":"4","key":"10.1016\/j.lfs.2022.120731_bb0100","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/hep.1840110407","article-title":"Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines","volume":"11","author":"Hann","year":"1990","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.lfs.2022.120731_bb0105","first-page":"2176","article-title":"Targeted co-delivery of the iron chelator deferoxamine and a HIF1\u03b1 inhibitor impairs pancreatic tumor growth","volume":"13","author":"Lang","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.lfs.2022.120731_bb0110","doi-asserted-by":"crossref","DOI":"10.2217\/fon.16.11","article-title":"Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence","author":"Chasen","year":"2016","journal-title":"Future Oncol."},{"issue":"12","key":"10.1016\/j.lfs.2022.120731_bb0115","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/jcph.966","article-title":"Bioequivalence of intravenous and Oral rolapitant: results from a randomized, open-label pivotal study","volume":"57","author":"Wang","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0120","article-title":"Examination of the antiproliferative activity of iron chelators","volume":"9","author":"Chaston","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.lfs.2022.120731_bb0125","first-page":"411","article-title":"An update on iron chelation therapy","volume":"10","author":"Poggiali","year":"2012","journal-title":"Blood Transfus."},{"key":"10.1016\/j.lfs.2022.120731_bb0130","doi-asserted-by":"crossref","unstructured":"D. J. Bonda, G. Liu, P. Men, G. Perry, M. A. Smith, and X. Zhu, \u201cNanoparticle Delivery of Transition-Metal Chelators to the Brain: Oxidative Stress will Never See it Coming!,\u201d CNS & Neurological Disorders - Drug Targets- CNS & Neurological Disorders), vol. 11, no. 1. pp. 81\u201385, [Online]. Available: https:\/\/www.ingentaconnect.com\/content\/ben\/cnsnddt\/2012\/00000011\/00000001\/art00010.","DOI":"10.2174\/187152712799960709"},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0928-0987(02)00241-5","article-title":"The influence of lipid nanocapsule composition on their size distribution","volume":"18","author":"Heurtault","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.lfs.2022.120731_bb0140","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1023\/A:1016121319668","article-title":"A novel phase inversion-based process for the preparation of lipid nanocarriers","volume":"19","author":"Heurtault","year":"2002","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.lfs.2022.120731_bb0145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2009.04.026","article-title":"Lipid nanocapsules: a new platform for nanomedicine","volume":"379","author":"Huynh","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2022.120731_bb0150","doi-asserted-by":"crossref","unstructured":"M. Nasr and S. Abdel-Hamid, \u201cLipid based Nanocapsules: A Multitude of Biomedical Applications\u201d, Current Pharmaceutical Biotechnology, vol. 16, no. 4. pp. 322\u2013332, [Online]. Available: https:\/\/www.ingentaconnect.com\/content\/ben\/cpb\/2015\/00000016\/00000004\/art00005.","DOI":"10.2174\/138920101604150218103555"},{"issue":"3","key":"10.1016\/j.lfs.2022.120731_bb0155","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jbm.a.30711","article-title":"Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake","volume":"78A","author":"Vonarbourg","year":"2006","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.lfs.2022.120731_bb0160","doi-asserted-by":"crossref","DOI":"10.1080\/02652040802055411","article-title":"Vesicular aceclofenac systems: a comparative study between liposomes and niosomes","author":"Nasr","year":"2008","journal-title":"J. Microencapsul."},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-47586-7","article-title":"Polymeric nanocapsular baicalin: chemometric optimization, physicochemical characterization and mechanistic anticancer approaches on breast cancer cell lines","volume":"9","author":"El-Gogary","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.lfs.2022.120731_bb0170","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3109\/10717544.2015.1092619","article-title":"Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery","volume":"23","author":"Nasr","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.lfs.2022.120731_bb0175","doi-asserted-by":"crossref","first-page":"106119","DOI":"10.1016\/j.ejps.2022.106119","article-title":"New repurposed rolapitant in nanovesicular systems for lung cancer treatment: Development, in-vitro assessment and in-vivo biodistribution study","author":"Kabil","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2022.120731_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2020.114605","article-title":"Deferasirox-loaded pluronic nanomicelles: synthesis, characterization, in vitro and in vivo studies","volume":"323","author":"Rahdar","year":"2021","journal-title":"J. Mol. Liq."},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.prp.2006.09.005","article-title":"Ehrlich tumor as model to study artificial hyperthyroidism influence on breast cancer","volume":"203","author":"Ferreira","year":"2007","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.lfs.2022.120731_bb0190","series-title":"Deferoxamine","author":"Velasquez","year":"2020"},{"issue":"6","key":"10.1016\/j.lfs.2022.120731_bb0195","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/blr.2006.25.697","article-title":"Guidance for industry: characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases","volume":"25","author":"Services","year":"2006","journal-title":"Biotechnol. Law Rep."},{"issue":"2","key":"10.1016\/j.lfs.2022.120731_bb0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"issue":"2","key":"10.1016\/j.lfs.2022.120731_bb0205","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-005-9066-y","article-title":"Validation of cyclin D1\/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression","volume":"95","author":"Grillo","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.lfs.2022.120731_bb0210","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jcmgh.2018.12.004","article-title":"Targeted delivery of Stk25 antisense oligonucleotides to hepatocytes protects mice against nonalcoholic fatty liver disease","volume":"7","author":"Cansby","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.lfs.2022.120731_bb0215","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/21655979.2020.1855914","article-title":"GIT1 overexpression promotes epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma","volume":"12","author":"Wang","year":"2021","journal-title":"Bioengineered"},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0225","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0027-5107(99)00010-X","article-title":"Lipid peroxidation\u2014DNA damage by malondialdehyde","volume":"424","author":"Marnett","year":"1999","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"issue":"2","key":"10.1016\/j.lfs.2022.120731_bb0230","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2004.12.005","article-title":"Glutathione peroxidase, glutathione-S-transferase, catalase, xanthine oxidase, Cu\u2013Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer","volume":"227","author":"Kaynar","year":"2005","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0009-8981(78)90081-5","article-title":"Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method","volume":"90","author":"Kei","year":"1978","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.lfs.2022.120731_bb0240","series-title":"Theory and Practice of Histological Techniques","author":"Bancroft","year":"2008"},{"issue":"22","key":"10.1016\/j.lfs.2022.120731_bb0245","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.lfs.2005.10.006","article-title":"Ascitic and solid ehrlich tumor inhibition by Chenopodium ambrosioides L. treatment","volume":"78","author":"Nascimento","year":"2006","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.lfs.2022.120731_bb0250","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12585","article-title":"Ameliorative effects of melatonin against solid ehrlich carcinoma progression in female mice","volume":"67","author":"Amin","year":"2019","journal-title":"J. Pineal Res."},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08982104.2015.1137313","article-title":"Augmented simvastatin cytotoxicity using optimized lipid nanocapsules: a potential for breast cancer treatment","volume":"27","author":"Safwat","year":"2017","journal-title":"J. Liposome Res."},{"issue":"February","key":"10.1016\/j.lfs.2022.120731_bb0260","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jconrel.2020.03.042","article-title":"Lipid nanocapsules to enhance drug bioavailability to the central nervous system","volume":"322","author":"Moura","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2022.120731_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118588","article-title":"Combinational drug-loaded lipid nanocapsules for the treatment of cancer","volume":"569","author":"Tsakiris","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.lfs.2022.120731_bb0270","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1039\/b617536h","article-title":"What is a green solvent? A comprehensive framework for the environmental assessment of solvents","volume":"9","author":"Capello","year":"2007","journal-title":"Green Chem."},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0275","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijpharm.2018.09.034","article-title":"Optimized acriflavine-loaded lipid nanocapsules as a safe and effective delivery system to treat breast cancer","volume":"551","author":"Montigaud","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2022.120731_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120217","article-title":"Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells","volume":"597","author":"Valsalakumari","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2022.120731_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110603","article-title":"Improved chemotherapeutic efficacy against resistant human breast cancer cells with co-delivery of docetaxel and thymoquinone by chitosan grafted lipid nanocapsules: formulation optimization, in vitro and in vivo studies","volume":"186","author":"Zafar","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.lfs.2022.120731_bb0290","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejpb.2019.12.016","article-title":"Co-encapsulation of docetaxel and thymoquinone in mPEG-DSPE-vitamin E TPGS-lipid nanocapsules for breast cancer therapy: formulation optimization and implications on cellular and in vivo toxicity","volume":"148","author":"Zafar","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.lfs.2022.120731_bb0295","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/08982104.2012.662653","article-title":"Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma","volume":"22","author":"Varshosaz","year":"2012","journal-title":"J. Liposome Res."},{"issue":"1","key":"10.1016\/j.lfs.2022.120731_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189950","article-title":"Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity","volume":"13","author":"Nehme","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.lfs.2022.120731_bb0305","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1039\/C6MD00293E","article-title":"Deferasirox-coated iron oxide nanoparticles as a potential cytotoxic agent","volume":"7","author":"Taghavi","year":"2016","journal-title":"Medchemcomm"},{"issue":"3","key":"10.1016\/j.lfs.2022.120731_bb0310","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1039\/C5NJ02790J","article-title":"Deferasirox loaded on fumed silica nanoparticles used in cancer treatment","volume":"40","author":"Taghavi","year":"2016","journal-title":"New J. Chem."},{"issue":"37","key":"10.1016\/j.lfs.2022.120731_bb0315","doi-asserted-by":"crossref","first-page":"24218","DOI":"10.1021\/acsomega.1c03816","article-title":"Preparation of pH-responsive vesicular deferasirox: evidence from in silico, in vitro, and in vivo evaluations","volume":"6","author":"Barani","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.lfs.2022.120731_bb0320","first-page":"6735","article-title":"Effects of deferoxamine on leukemia in vitro and its related mechanism","volume":"24","author":"Yang","year":"2018","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.lfs.2022.120731_bb0325","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1155\/2022\/8281267","article-title":"Deferoxamine inhibits acute lymphoblastic leukemia progression through repression of ROS\/HIF-1\u03b1, Wnt\/\u03b2-catenin, and p38MAPK\/ERK pathways","volume":"vol","author":"You","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.lfs.2022.120731_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120500","article-title":"Ferulic acid nanocapsules as a promising treatment modality for colorectal cancer: preparation and in vitro\/in vivo appraisal","volume":"298","author":"El-Gogary","year":"2022","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.lfs.2022.120731_bb0335","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.sjbs.2016.12.001","article-title":"Ifosfamide-loaded lipid-core-nanocapsules to increase the anticancer efficacy in MG63 osteosarcoma cells","volume":"25","author":"Wang","year":"2018","journal-title":"Saudi J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.lfs.2022.120731_bb0340","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/0039-128X(75)90110-5","article-title":"MCF-7: a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors","volume":"26","author":"Horwitz","year":"1975","journal-title":"Steroids"},{"issue":"15","key":"10.1016\/j.lfs.2022.120731_bb0345","first-page":"3071","article-title":"MCF-7: the first hormone-responsive breast cancer cell line","volume":"57","author":"Levenson","year":"1997","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.lfs.2022.120731_bb0350","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1749-6632.1956.tb50902.x","article-title":"Study of metastasis with the aid of labeled ascites tumor cells","volume":"63","author":"Ambrus","year":"1956","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"13","key":"10.1016\/j.lfs.2022.120731_bb0355","first-page":"2375","article-title":"Ehrlich ascites carcinoma","volume":"10","author":"Ozaslan","year":"2011","journal-title":"Afr. J. Biotechnol."},{"issue":"7","key":"10.1016\/j.lfs.2022.120731_bb0360","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrc1887","article-title":"Drug interactions in cancer therapy","volume":"6","author":"Scripture","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.lfs.2022.120731_bb0365","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.lfs.2022.120731_bb0370","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0009-9120(99)00022-3","article-title":"Evaluation of oxidative stress parameters in blood of patients with laryngeal carcinoma","volume":"32","author":"Seven","year":"1999","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.lfs.2022.120731_bb0375","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF03179070","article-title":"Superoxide dismutases: a physiopharmacological update","volume":"65","author":"Valdivia","year":"2009","journal-title":"J. Physiol. Biochem."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522004313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522004313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:03:29Z","timestamp":1758402209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522004313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":75,"alternative-id":["S0024320522004313"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120731","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120731"}}